Literature DB >> 23519750

Imaging of chronic inflammatory bowel disease with 18F-FDG PET in children and adolescents.

L D Berthold1, D Steiner, D Scholz, G Alzen, K-P Zimmer.   

Abstract

Standard for diagnosis of inflammatory bowel disease (IBD) is the endoscopy of the stomach and the intestine. Aim of this study was to determine the value of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in pediatric patients with mild to moderate IBD.We included 23 children and adolescents between 8 and 17 years (median 15 years, 13 boys, 10 girls) in this retrospective study in a routine clinical setting. Diagnoses were Crohn's disease in 19 and ulcerative colitis in 4 cases.3 children had a conventional FDG-PET, 20 patients a combined FDG-PET-computed tomography exam. All children had upper and lower intestinal endoscopy with biopsy and a Hydro-MRI exam to assess the jejunum and proximal ileum. The gastrointestinal tract was divided in 7 segments: Stomach plus duodenum, jejunum and proximal ileum, terminal ileum, cecum plus ascending colon, transverse colon, descending colon, and rectosigmoid.Superficial gastric lesions were missed, gastric ulcerations were detected. For the stomach, the sensitivity was 0.25, the specificity was 1.00, the positive predictive value was 1.00, for the lower intestine (terminal ileum and colon) the values were 0.74, 0.88, and 0.96; for the terminal ileum 0.89, 0.75 and 0.94, respectively.The sensitivity and specificity for of ileal and colonic lesions is high. FDG-PET has to be discussed as a tool for the determination of extent and degree of inflammation, especially in those parts of the small bowel that are not accessible to endoscopy. This has to be weighed against the additional radiation exposure administrated. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23519750     DOI: 10.1055/s-0033-1334878

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  6 in total

1.  PET/CT in the diagnosis of inflammatory bowel disease in pediatric patients: a review.

Authors:  Mikkel Malham; Søren Hess; Rasmus G Nielsen; Steffen Husby; Poul Flemming Høilund-Carlsen
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-04-25

2.  Diagnostic performance of PET/MR in the evaluation of active inflammation in Crohn disease.

Authors:  Onofrio Antonio Catalano; Vincent Wu; Umar Mahmood; Alberto Signore; Mark Vangel; Andrea Soricelli; Marco Salvatore; Debra Gervais; Bruce R Rosen
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

Review 3.  Imaging Inflammation - From Whole Body Imaging to Cellular Resolution.

Authors:  Tuula Peñate Medina; Jan Philip Kolb; Gereon Hüttmann; Robert Huber; Oula Peñate Medina; Linh Ha; Patricia Ulloa; Naomi Larsen; Arianna Ferrari; Magdalena Rafecas; Mark Ellrichmann; Mariya S Pravdivtseva; Mariia Anikeeva; Jana Humbert; Marcus Both; Jennifer E Hundt; Jan-Bernd Hövener
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

4.  Role of molecular imaging in the management of patients affected by inflammatory bowel disease: State-of-the-art.

Authors:  Federico Caobelli; Laura Evangelista; Natale Quartuccio; Demetrio Familiari; Corinna Altini; Angelo Castello; Mariapaola Cucinotta; Rossella Di Dato; Cristina Ferrari; Aurora Kokomani; Iashar Laghai; Riccardo Laudicella; Silvia Migliari; Federica Orsini; Salvatore Antonio Pignata; Cristina Popescu; Erinda Puta; Martina Ricci; Silvia Seghezzi; Alessandro Sindoni; Martina Sollini; Letterio Sturiale; Anna Svyridenka; Vittoria Vergura; Pierpaolo Alongi
Journal:  World J Radiol       Date:  2016-10-28

5.  An EGFR targeted PET imaging probe for the detection of colonic adenocarcinomas in the setting of colitis.

Authors:  N Selcan Turker; Pedram Heidari; Raju Kucherlapati; Melanie Kucherlapati; Umar Mahmood
Journal:  Theranostics       Date:  2014-07-01       Impact factor: 11.556

Review 6.  The Role of MR Enterography in Assessing Crohn's Disease Activity and Treatment Response.

Authors:  Matthew P Moy; Jenny Sauk; Michael S Gee
Journal:  Gastroenterol Res Pract       Date:  2015-12-27       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.